Clinical Trials Browser

Unknown × Observational × Idarubicin × Clear all

NCT01889407 2015-04-21

Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients

Other hematologic neoplasm

Leukemia, Myeloid, Acute